Ron inhibitors for use in preventing and treating bone loss

Patent metadata

Field	Value
Publication number	US-9907791-B2
Application number	US-201515122353-A
Country	US
Kind code	B2
Filing date	Mar 13, 2015
Priority date	Mar 14, 2014
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

Provided herein are methods for inhibiting osteolysis or treating osteoporosis in a subject in need thereof, the method including administering to the subject at least one RON inhibitor. The osteolysis may be caused by a condition selected from the group consisting of cancer, inflammation, and cyst. The condition may include a bone tumor or a tumor located in bone. The subject may have been diagnosed with bone cancer. The inhibitor may be ASLAN002. The inhibitor may be OSI-296. The inhibitor may be selective or specific for RON. The inhibitor may not depend on the function of RANKL or TGFβ.

First claim

We claim:

1. A method for inhibiting osteolysis or treating osteoporosis in a subject in need thereof, the method comprising administering to the subject a composition comprising an effective amount of at least one Recepteur d'Origine Nantais (RON) inhibitor selected from the group consisting of OSI-296 and ASLAN002.

2. The method of claim 1 , wherein the subject has been diagnosed with a condition selected from the group consisting of inflammation, cyst, and cancer.

3. The method of claim 2 , wherein the subject has been diagnosed with cancer with bone metastasis or cancer-mediated bone destruction.

4. The method of claim 2 , wherein the cancer is selected from the group consisting of lymphoma, lung cancer, pancreatic cancer, breast cancer, rectal cancer, colon cancer, stomach cancer, larynx cancer, liver cancer, brain cancer, and skin cancer.

5. The method of claim 1 , wherein the osteolysis is caused by a condition selected from the group consisting of tumor, inflammation, and cyst.

6. The method of claim 5 , wherein the condition comprises a bone tumor or a tumor located in bone.

7. The method of claim 1 , wherein the subject is premenopausal.

8. The method of claim 1 , wherein the subject is menopausal.

9. The method of claim 1 , wherein the subject is postmenopausal.

10. The method of claim 1 , wherein the RON inhibitor does not depend on the function of RANKL or TGFβ.

Assignees

• Univ Utah Res Found

Inventors

• Welm Alana L
• Andrade Kelsi Kretschmann

Classifications

• A61K31/4355 Primary

  the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom · CPC title

• A61K31/444 Primary

  containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title

• A61K31/4412

  having oxo groups directly attached to the heterocyclic ring · CPC title

• C07D491/02

  in which the condensed system contains two hetero rings · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title